- Home
- BPMC
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Upcoming Earnings Alert:
Get ready for potential market movements as Blueprint Medicines Corporation BPMC prepares to release earnings report on 31 Jul 2025.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 8.3B | IPO Year: | 2015 |
| Target Price: | $128.87 | AVG Volume (30 days): | 4.3M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $73.04 - $129.65 | Next Earning Date: | 07-31-2025 |
| Revenue: | $562,121,000 | Revenue Growth: | 99.19% |
| Revenue Growth (this year): | 44.46% | Revenue Growth (next year): | 32.78% |
Stock Insider Trading Activity of Blueprint Medicines Corporation (BPMC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carter Percy H. | BPMC | CHIEF SCIENTIFIC OFFICER | Jun 3 '25 | Sell | $127.88 | 2,659 | $340,032.92 | 56,624 | |
| Albers Jeffrey W. | BPMC | Director | May 27 '25 | Sell | $101.48 | 5,000 | $505,691.50 | 146,630 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | May 19 '25 | Sell | $100.84 | 2,274 | $228,557.31 | 64,718 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | May 5 '25 | Sell | $102.28 | 2,274 | $231,386.14 | 64,718 | |
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | May 5 '25 | Sell | $103.62 | 2,752 | $283,818.52 | 18,444 |
Latest Blueprint Medicines Corporation News
BPMC Breaking Stock News: Dive into BPMC Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Exploring US High Growth Tech Stocks For Potential Opportunities
Insider Monkey
a month ago
Blueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic Mastocytosis
Simply Wall St.
a month ago
Exploring 3 High Growth Tech Stocks In The US Market
Simply Wall St.
a month ago
Exploring 3 High Growth Tech Stocks in the US Market
Simply Wall St.
a month ago
Exploring Three High Growth Tech Stocks In The US Market
MT Newswires
a month ago
Wells Fargo Downgrades Blueprint Medicines to Equalweight From Overweight, Price Target is $129
Simply Wall St.
a month ago
Exploring High Growth Tech Opportunities in US Markets
PR Newswire
a month ago
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
Compare BPMC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPMC Blueprint Medicines Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.